|
|
|
市場調查報告書
細胞因子治療及抑製劑：研發產品線、市場、策略性挑戰 - 概要
Cytokine-Based Therapies and Inhibitors: R&D Pipelines, Markets, and Strategic Issues - Overview
|
細胞因子治療及抑製劑：研發產品線、市場、策略性挑戰 - 概要 是由出版商Insight Pharma Reports在2011年09月所出版的。
這份英文市場調查報告書價格從美金2495起跳。
細胞因子治療、細胞因子治療抑製劑及其受體市場極具吸引力，因此競爭激烈。目前共有超過120間企業進行270種新興治療方式研發。細胞因子治療及抑製劑於25年前既已上市，每年具有10億美金之銷售，雖已是成熟市場，但仍存在製藥公司應該追求之眾多機會。
本報告為，匯整已上市之細胞因子治療及抑製劑概要、新興治療方式、開發產品線及標靶適應、臨床數據、市場現況、銷售數據、挑戰等市場趨勢，以下列摘要形式闡述。
實施概要
第1章 簡介及背景
- 細胞因子概要
- 干擾素
- 白細胞介素
- 腫瘤壞死因子組
- 造血生長因子
- 趨化因子
- 轉化生長因子－β
- 本報告範圍
第2章 目前已上市之細胞因子治療
- 干擾素
- 白細胞介素及其抑製劑
- 腫瘤壞死因子（TNF）組抑製劑
- 造血生長因子
- 趨化因子抑製劑
第3章 新興之細胞因子治療
- 干擾素
- 白細胞介素
- 腫瘤壞死因子（TNF）組抑製劑
- 造血生長因子
- 其他開發中細胞因子治療
第4章 阻礙細胞因子治療及細胞因子受體之新興治療
- 干擾素
- 白細胞介素
- 腫瘤壞死因子（TNF）組抑製劑
- 造血生長因子
- 趨化因子抑製劑
- 其他細胞因子治療抑製劑
第5章 商業及策略性考量
- 目前細胞因子產品及抑製劑之銷售
- 以新興細胞因子治療為標靶之市場／疾病／症狀
- 癌症
- 貧血
- 自身免疫性疾病
- 呼吸系統疾病
- 感染
- B型肝炎
- C型肝炎
- HIV
- 其他
- 阻礙細胞因子及受體之治療
- 細胞因子產品及抑製劑領域之個別化治療
- 企業面臨挑戰及競爭
第6章 專家訪談
參考
企業名錄
Abstract
Emerging cytokine-based therapies, and inhibitors of cytokines and their
receptors, represent attractive markets that have become highly competitive.
More than 120 companies are developing over 270 new therapies that either are
cytokines, mimic cytokines, or inhibit cytokines and/or cytokine receptors.
This report examines:
- Marketed cytokine-based therapies and inhibitors, and emerging new
therapies
- Activities to expand approved indications for cytokines and cytokine
inhibitors
- Pipeline of cytokine therapies and inhibitors in development, their
targeted indications, clinical progress/data, issues or hurdles
- Current and potential markets for cytokines and cytokine inhibitors
- Market trends including sales data, major challenges for companies working
in this field, and strategic considerations
Also included are interviews conducted by Insight Pharma Reports with experts
in this field.
In the past 25 years, numerous cytokine-based therapies and inhibitors of
cytokines and their receptors have reached the market, with several of these
products attaining over $1 billion in annual sales. Several such therapies
represent established markets, but there are many new opportunities being
pursued by pharmaceutical companies.
Cytokines are a large, diverse group of extracellular proteins that are
produced by cells of the immune system and that act by binding to cytokine
receptors on targeted cells, thus initiating a signaling cascade within those
cells. Following a brief overview of cytokines and their classification, this
report focuses on cytokine-based therapies and inhibitors that are currently
marketed plus emerging new therapies. Our discussion of approved cytokine
therapies and inhibitors includes activities to expand their approved
indications and markets where relevant. A table of these currently marketed
products encompasses some early biosimilars.
Cytokine-Based Therapies and Inhibitors: R&D Pipelines, Markets, and
Strategic Issues next turns to an examination of the development pipeline
of cytokine-based therapies. We begin by discussing selected emerging cytokine
therapies, companies developing these therapies, the targeted indications,
clinical progress or data (if available), and issues or hurdles that some
specific emerging therapies may be facing. Extensive tables of emerging
cytokine therapies accompany this discussion. We then turn to a discussion of
emerging therapies that block cytokines or their receptors, thus blocking the
interaction of cytokines and their receptors and therefore their activity,
considering the same issues as for emerging cytokine therapies. Tables of
emerging cytokine inhibitors accompany this discussion.
The extensive tables and discussion included in Cytokine-Based Therapies
and Inhibitors: R&D Pipelines, Markets, and Strategic Issues demonstrate
the high levels of interest and competition in this field. We discuss business
and strategic considerations that a company in this field should be aware of.
This includes information about the market for available cytokine-based
products and inhibitors (including current sales of major products), plus
brief discussions of the current and potential markets for emerging cytokine
therapies and inhibitors, which can potentially be used for a wide spectrum of
diseases. In addition, market trends, major challenges and hurdles, and other
strategic issues are considered, including diseases that are targeted by
emerging cytokine therapies and inhibitors, the role of personalized medicine
in the field of cytokine-based products and inhibitors, and insights gleaned
through interviews conducted with experts in the field.
About the Author
Lucy J. Sannes, PhD, MBA, is president of Sannes & Associates, a
consulting firm specializing in evaluation and management of the biosciences.
Before forming Sannes & Associates, she held management positions at Genetic
Systems and Abbott Laboratories in product development, product support, and
technical marketing. Dr. Sannes received her PhD in biological chemistry from
the University of Michigan and her MBA from Seattle Pacific University.
Table of Contents
Executive Summary
Chapter 1 Introduction and Background
- 1.1. Overview of Cytokines
- Interferons
- Interleukins
- Tumor Necrosis Factor Family
- Hematopoietic Growth Factors
- Chemokines
- Transforming Growth Factor-β
- 1.2. Scope of the Report
Chapter 2 Cytokine-Based Therapies on the Market Today
- 2.1. Interferons
- Interferon Alpha
- Interferon Beta
- Interferon Gamma
- 2.2. Interleukins and Interleukin Inhibitors
- Interleukin 1 Inhibitors
- Interleukin 2 and Interleukin 2 Receptor Inhibitors
- Interleukin 6 Inhibitor
- Interleukin 11
- Interleukin 12/23 Inhibitor
- 2.3. Inhibitors of the Tumor Necrosis Factor (TNF) Family
- Tumor Necrosis Factor Inhibitors
- BLyS Inhibitor
- RANKL Inhibitor
- CD30 Inhibitor
- 2.4. Hematopoietic Growth Factors
- Erythropoietin (EPO) and Erythropoiesis-Stimulating Agents
- Granulocyte-Colony Stimulating Factor (G-CSF)
- Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF)
- Stem Cell Factor (SCF)
- Thrombopoietin (TPO)
- 2.5. Chemokine Inhibitors
- CXCR4 Inhibitor
- CCR5 Co-Receptor Antagonist
Chapter 3 Emerging Cytokine Therapies
- 3.1. Interferons
- Amarillo Biosciences' Interferon Alpha Lozenge (Oral Interferon Alpha)
- Biogen Idec' s PEGylated Interferon Beta-1a
- Biolex Therapeutics' Locteron
- Bristol-Myers Squibb' s PEG Interferon λ
- Flamel Technologies' IFN-α XL
- Helix BioPharma' s Topical Interferon Alpha 2b
- Nuron Biotech' s NU100 and NU400
- 3.2. Interleukins
- Bristol-Myers Squibb' s IL-21
- EGEN' s EGEN-001
- Philogen' s Darleukin (L19-IL2)
- Philogen' s Teleukin (F16-IL2)
- Transgene' s TG4010 (MVA-MUC1-IL2)
- Transgene' s TG4001
- 3.3. Tumor Necrosis Factor (TNF) Family
- GenVec' s TNFerade
- Human Genome Sciences' Mapatumumab
- Memgen' s ISF35
- MolMed' s NGR-hTNF
- Philogen' s Fibromun (L19-TNF)
- 3.4. Hematopoietic Growth Factors
- Affymax' and Takeda Pharmaceutical' s Peginesatide
- Amgen' s OncoVEXGM-CSF
- BioSante Pharmaceuticals' GVAX Cancer Vaccines
- Jennerex Biotherapeutics and Transgene' s JX594/TG6006 (VVTK-/GM-CSF)
- Maxygen' s Maxy-G34
- SYGNIS Pharma' s AX200
- Teva Pharmaceutical Industries' Lipegfilgrastim and CG-10639
- 3.5. Selected Other Cytokines in Development
- CEL-SCI' s Multikine
- TissueGene' s TissueGene-C (TG-C)
Chapter 4 Emerging Therapies that Block Cytokines or Cytokine Receptors
- 4.1. Interferon Inhibitors
- AstraZeneca' s Sifalimumab (MEDI-545)
- Roche/Genentech' s Rontalizumab
- 4.2. Interleukin Inhibitors
- Abbott' s Briakinumab (ABT-874)
- Abbott' s and Biogen Idec' s Daclizumab
- Alder Biopharmaceuticals' ALD518/Bristol-Myers-Squibb' s BMS945429
- Amgen' s AMG 827
- AstraZeneca' s MEDI-528, MEDI-563, and Tralokinumab (CAT-354)
- Cephalon' s CINQUIL (Reslizumab)
- Eli Lilly' s LY2439821
- GlaxoSmithKline' s Bosatria (Mepolizumab)
- Janssen Biotech' s Siltuximab (CNTO 328) and CNTO 136
- Novartis' Secukinumab
- Novartis' QAX576
- Novo Nordisk' s NN8226
- Pfizer' s Anrukinzumab
- Roche/Genentech' s Lebrikizumab
- Sanofi' s and Regeneron' s Sarilumab (REGN88/SAR153191)
- XOMA' s Gevokizumab (XOMA 052)
- 4.3. Tumor Necrosis Factor (TNF) Family Inhibitors
- Amgen' s and Takeda Pharmaceutical' s Conatumumab (AMG 655)
- Anthera Pharmaceuticals' Blisibimod
- Apogenix' APG101
- AstraZeneca' s AZD9773 (CytoFab)
- Cephalon' s CEP-3727
- Eli Lilly' s LY2127399
- ESBATech' s (Alcon' s) ESBA105
- Merck Serono' s Atacicept
- Neovacs' TNF-Kinoid
- Pfizer' s and Ablynx' Ozoralizumab (ATN-103) and PF-05230905 (ATN-102)
- Roche/Genentech' s RG7416
- 4.4. Transforming Growth Factor-Beta Inhibitors
- Antisense Pharma' s Trabedersen
- BTG' s Pleneva
- Eli Lilly' s LY2157299 and LY2382770
- NovaRx' Lucanix
- 4.5. Hematopoietic Growth Factor Inhibitors
- AstraZeneca' s and CSL' s CAM-3001
- 4.6. Chemokine Inhibitors
- AstraZeneca' s AZD2423 and AZD5069
- GlaxoSmithKline' s 1605786 (ChemoCentryx' Traficet-EN)
- ChemoCentryx' CCX354
- ChemoCentryx' CCX140
- GlaxoSmithKline' s 656933
- Kyowa Hakko Kirin' s KW-0761 and Amgen' s AMG 761 (Mogamulizumab)
- Progenics Pharmaceuticals' PRO 140
4.7. Other Cytokine Inhibitors
Chapter 5 Business and Strategic Considerations
- 5.1. Current Sales of Cytokine-Based Products and Cytokine Inhibitors
- 5.2. Selected Markets/Diseases/Conditions Targeted by Emerging Cytokine
Therapies and Therapies That Inhibit Activity of Cytokines and Their Receptors
- Cancer
- Anemia
- Autoimmune Diseases
- Respiratory Diseases
- Infectious Diseases
- Hepatitis B
- Hepatitis C
- HIV
- Other Disease Opportunities
- 5.3. Personalized Medicine in the Field of Cytokine-Based Products and
Cytokine Inhibitors
- 5.4. Selected Challenges and Hurdles Being Faced by Companies in the Field
of Cytokine-Based Products and Cytokine Inhibitors
Chapter 6 Expert Interviews
- 6.1. Hubert Heinrichs, MD, PhD, Chief Medical Officer and Acting CEO, and
Andrea Kottke, PhD, Head of Marketing, Antisense Pharma
- 6.2. Thomas Hoger, PhD, Chief Executive Officer and Chief Financial
Officer, Apogenix
- 6.3. Josefin-Beate (Josi) Holz, MD, Chief Medical Officer, Ablynx
- 6.4. John Sims, Scientific Executive Director, Inflammation Research, Amgen
- 6.5. John McPherson, PhD, Senior Vice President, Biologics Research and
Development, Genzyme
References
Company Index
TABLES
- Table 1.1. Overview of Interleukins
- Table 1.2. Tumor Necrosis Factor (Ligand) and Tumor Necrosis Factor
Receptor Superfamilies
- Table 1.3. The Chemokine Superfamily
- Table 2.1. Selected Interferon Products on the Market
- Table 2.2. Selected Interleukin Products on the Market
- Table 2.3. Selected Cytokine Members of the TNF Family on the Market
- Table 2.4. Selected Hematopoietic Growth Factors and Growth Factor
Inhibitors on the Market
- Table 2.5. Selected Chemokine Inhibitors on the Market
- Table 3.1. Selected Interferon Products in Development
- Table 3.2. Selected Interleukin Products in Development
- Table 3.3. Selected Cytokine Members of the TNF Family in Development
- Table 3.4. Selected Hematopoietic Growth Factors in Development
- Table 3.5. Selected Chemokines in Development
- Table 3.6. Selected Transforming Growth Factor Beta (TGFβ) Products
in Development
- Table 3.7. Selected Products with Multiple Cytokines and Cytokine Mixtures
in Development
- Table 4.1. Selected Interferon Inhibitors and Interferon Receptor
Inhibitors in Development
- Table 4.2. Selected Interleukin Inhibitors and Interleukin Receptor
Inhibitors in Development
- Table 4.3. Selected Inhibitors of the TNF Family in Development
- Table 4.4. Selected Transforming Growth Factor Beta Inhibitors in
Development
- Table 4.5. Selected Hematopoietic Growth Factor Inhibitors in Development
- Table 4.6. Selected Chemokine Inhibitors in Development
- Table 4.7. Selected Other Cytokine Inhibitors in Development
- Table 5.1. Sales of Selected Cytokine-Based Therapies and Therapies That
Inhibit Cytokines or Their Receptors
- Table 5.2. Incidence and Mortality of Selected Cancers in the United
States, 2011
- Table 5.3. Five-Year Relative Survival Rates by Stage at Diagnosis, 1999 -
2006, for Selected Major Cancers
- Table 5.4. Prevalence of Selected Autoimmune Diseases in the United States
FIGURES
- Figure 1.1. Chemokine Superfamily Arranged by Receptors
- Figure 6.1. TGF-b2 Signaling Pathway
|
 |
